Showing results (321-330 of 574) with videos related to

Sort By:
Pageof 58
Investigational New Drugs|April 1, 1988
Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanomaA Polyzos, S S Legha, A M Burgess, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1987
Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patientsV Fainstein, G P Bodey, L Elting, et al.
Cancer Treatment Reports|March 1, 1985
Phase II trial of mitogauzone in malignant primary brain tumorsL G Feun, W K Yung, D J Stewart, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1989
Oral ciprofloxacin therapy for infections in cancer patientsE Haron, K V Rolston, C Cunningham, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1983
Clinical pharmacology of ceftriaxone in patients with neoplastic diseaseP Salvador, R G Smith, R E Weinfeld, et al.
Cancer Investigation|January 1, 1983
Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disordersG Lopez-Berestein, F Cabanillas, B M Osborne, et al.
American Journal of Clinical Oncology|October 1, 1982
Phase II clinical evaluation of AZQ in colorectal cancerA Y Bedikian, J R Stroehlein, D A Karlin, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 1, 1991
In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancerK V Rolston, M Messer, H Nguyen, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1986
Imipenem/cilastatin as secondary therapy for infections in cancer patientsG P Bodey, K Rolston, P Jones, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1990
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patientsK V Rolston, H Nguyen, M Messer, et al.
Pageof 58